Enochian BioSciences Completes Pre-IND After FDA Comments
October 18 2021 - 8:09AM
Dow Jones News
By Chris Wack
Enochian BioSciences Inc. Monday said it completed an
investigator pre-investigational new drug process following receipt
of written comments from the U.S. Food and Drug Administration's
Center for Biologics Evaluation and Research Office of Tissues and
Advanced Therapies.
The company said the request was based on the results of a
54-year old man living with HIV who had failed to suppress the
virus with antiviral therapy. The patient subsequently stopped
taking ART and received an innovative treatment developed by
SRI.
Enochian BioSciences holds the exclusive license for the
product.
The company said the patient's HIV infection blood levels were
controlled more effectively for 365 consecutive days off ART using
the SRI treatment compared to what had previously been achieved
with ART.
Enochian shares rose 3% to $8.90 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 18, 2021 07:54 ET (11:54 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.